

Pegaspargase - Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, or Mixed/Biphenotypic Leukemia

(This form must be completed before the first dose is dispensed.)

1. Patient Profile

- * Surname:
- * Given Name:
- * OHIN: * Chart Number:
- * Postal Code:
- * Height (cm): * Weight (kg):
- * BSA (m²): * Gender: ☐ Male ☐ Female ☐ Other
- * Date of Birth:
Day Month Year
- * Site:
- * Attending Physician (MRP- Most Responsible Physician):
- Requested Prior Approval ☐ Yes

Request prior approval for enrolment

- * Justification for Funding
-

2. Eligibility Criteria

The patient must meet the following criteria:

- Pegaspargase is used as part of a multi-agent regimen for the treatment of relapsed or refractory pediatric^{1,2} acute lymphoblastic leukemia, lymphoblastic lymphoma or mixed/biphenotypic leukemia. ☐ Yes

- The patient is eligible for pegaspargase if the diagnosis occurred prior to 18 years of age.
- If the diagnosis occurred at 18 or 19 years of age, the patient is eligible for CCO funding if pegaspargase is administered at a POGO-affiliated pediatric cancer centre or satellite site and the patient's care is managed by a pediatric oncology service.

3. Baseline Information

- a. Protocol (*or Standard of Care protocol equivalent):

Note: Patients are eligible for CCO funding of pegaspargase if used as part of the standard of care backbone of the COG clinical trial.

- ☐ UK ALL R3*
☐ AALL1331*
☐ Other

Other (specify):

.....

4. Funded Dose

Pegaspargase up to 2,500U/m²/dose IV or IM

5. Notes

- Pegaspargase will be reimbursed on a per vial basis.

6. Supporting Documents

None required.

In the event of an audit, the following should be available to document eligibility:

- A clinic note confirming the patient diagnosis, relapsed/refractory disease, and protocol.

Signature of Attending Physician (MRP-Most Responsible Physician):

.....
Day Month Year